CoChat

Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Introduction Alzheimer’s disease (AD) is the most common form of dementia, and four medications are currently available as symptomatic therapies: three cholinesterase inhibitors (ChEI) and memantine. In June 2021, aducanumab was approved in the United States under an accelerated approval pathway as the first novel putative disease-modifying therapy (p-DMT) targeting the β-amyloid (Aβ) cascade in the brain. The combination of several monotherapies to address the multifactorial pathogenesis of neurodegenerative diseases is an anticipated next step.Areas covered The cholinergic hypothesis and the amyloid cascade hypothesis have been proposed as explanations for the pathogenesis of AD. Given the limited effectiveness of monotherapies based on these hypotheses, approaches using combination therapy are attempting to address the complexity of AD pathogenesis, including putative causative proteins-related neurodegeneration, neurotransmitters, and neuroinflammation, in a comprehensive manner.Expert opinion The efficacy of an initial or add-on combination approach to counteracting neurodegenerative processes and functional deterioration has been investigated. The combination of symptomatic therapies with approved anti-dementia medicines (one ChEI and memantine) has been found to be functionally effective for a moderately severe disease stage. Furthermore, combination strategies involving p-DMTs, symptomatic therapies, and neuro-regeneration may be useful in the future.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2022.2042514

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 63 references

Research works printed but not linked: 7

  1. Matsunaga S, 2014, Int J Neuropsychopharmacol, 18, 115
  2. Koola MM, 2018, J Geriatr Care Res, 5, 57
  3. Daruich A, 2019, Mol Vis, 25, 610
  4. Ismail R, 2018, Int J Alzheimers Dis, 2018, 6852303
  5. Russ TC, 2012, Cochrane Database Syst Rev, 2012, CD009132
  6. Ruthirakuhan MT, 2018, Cochrane Database Syst Rev, 5, CD012197
  7. Salloway S, 2021, JAMA Neurol, 79, e214161

Cited by

See all 13

Metadata

Authors
Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M.
Affiliations
  • Jikei University School of Medicine (JP)
  • Keio University (JP)
Corresponding author
Mimura, Masaru
Venue
Expert Opinion on Pharmacotherapy
Published
2022-03-01
Volume
23
Issue
6
Pages
727-737
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W4214559958
Cited by
11
References
62
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 5
FWCI
1.40
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
not funded
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, combination therapy, cholinesterase inhibitors, memantine, aducanumab, disease-modifying therapy, amyloid hypothesis, cholinergic hypothesis, neuroinflammation, neurodegeneration, adjunctive therapy, nerve regeneration
MeSH terms
Alzheimer Disease, Cholinesterase Inhibitors, Drug Therapy, Combination, Humans, Memantine, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14656566.2022.2042514
The paper
Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022). Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2022.2042514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.